Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 297 pages

Showing 201 - 250


lung cancer

No Benefit of Adding Gefitinib to Platinum-Based Doublet in EGFR-Mutant NSCLC After Progression on First-Line Gefitinib

In a phase III IMPRESS trial reported in The Lancet Oncology, Soria et al found no progression-free survival benefit of adding gefitinib (Iressa) to platinum-based doublet chemotherapy in patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC) who had acquired resistance to...

lung cancer

Afatinib Improves Progression-Free Survival vs Erlotinib in Second-Line Treatment of Advanced Squamous Cell Carcinoma of the Lung

In the phase III LUX-Lung 8 trial reported in The Lancet Oncology, Soria et al found that the irreversible ErbB-family inhibitor afatinib (Gilotrif) significantly improved progression-free and overall survival vs the EGFR tyrosine kinase inhibitor erlotinib as second-line treatment in patients with ...

lung cancer

Postoperative Radiation Therapy May Improve Overall Survival in Incompletely Resected Stage II or III NSCLC

In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Wang et al found that postoperative radiation therapy has been declining in use in recent years but is associated with improved overall survival in patients with incompletely resected stage II or III...

lung cancer
issues in oncology

Pooled Analysis Shows Activity of Afatinib Differs in NSCLC According to Uncommon EGFR Mutations

In a pooled analysis of the LUX-Lung 2, 3, and 6 trials reported in The Lancet Oncology, Yang et al found that the activity of afatinib (Gilotrif) differed according to uncommon EGFR mutations in advanced non–small cell lung cancer (NSCLC). Most patients with EGFR-mutant NSCLC have deletion...

lung cancer

Addition of Necitumumab to First-Line Gemcitabine-Cisplatin Improves Overall Survival in Stage IV Squamous NSCLC

In the phase III SQUIRE trial reported in The Lancet Oncology, Thatcher et al found that the addition of the second-generation epidermal growth factor receptor (EGFR) antibody necitumumab to first-line gemcitabine-cisplatin improved overall survival among patients with stage IV squamous...

lung cancer

Bronchial Gene-Expression Classifier Improves Bronchoscopy Performance in Diagnosing Lung Cancer

In a study reported in The New England Journal of Medicine, Silvestri et al of the AEGIS study team found that use of a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy in patients being evaluated for suspected lung cancer. Study Details The study...

lung cancer

Phase III Trial Confirms Benefit of Adding Bevacizumab to Chemotherapy in Chinese Patients With Advanced NSCLC

In a phase III BEYOND trial reported in the Journal of Clinical Oncology, Zhou et al found that the addition of bevacizumab to carboplatin-paclitaxel improved progression-free and overall survival in Chinese patients with locally advanced, metastatic, or recurrent advanced nonsquamous...

lung cancer

Histologic Subtype Classification of Lung Adenocarcinoma Predicts Disease-Free but Not Overall Survival Benefit From Adjuvant Chemotherapy

In an analysis reported in the Journal of Clinical Oncology, Tsao et al found that classification by histologic subtype for invasive lung adenocarcinoma was not predictive of overall survival benefit of adjuvant therapy in patients undergoing complete resection but did appear to predict benefit of...

lung cancer

Meta-Analysis Shows Increased Benefit of EGFR Tyrosine Kinase Inhibitors vs Chemotherapy in Subgroups of Patients With EGFR-Mutant NSCLC

In a meta-analysis reported in the Journal of Clinical Oncology, Lee et al found that increased progression-free survival benefit of EGFR tyrosine kinase inhibitor treatment vs chemotherapy was exhibited in patients with exon 19 deletion, never-smokers, and women. Study Details The meta-analysis...

lung cancer
issues in oncology

Targeted Massively Parallel Sequencing Study Indicates Similarity of Somatic Driver Mutations in NSCLC for African American vs European Ancestry

In a study reported in the Journal of Clinical Oncology, Araujo et al used targeted massively parallel sequencing to produce an in-depth molecular profile of non–small cell lung cancer (NSCLC) in African Americans. Comparison with findings in patients of European/white ancestry with NSCLC...

lung cancer

Immune Checkpoint Inhibitor Nivolumab Active in Heavily Pretreated Advanced NSCLC

In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Gettinger et al found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo) produced durable responses and promising survival rates in patients...

lung cancer

EGFR Inhibitor Rociletinib Active in EGFR T790M Mutation–Positive NSCLC Previously Treated With EGFR Inhibitors

In a phase I/II study reported in The New England Journal of Medicine, Sequist et al found that rociletinib—an EGFR inhibitor active in the presence and absence of the EGFR T790M mutation known to mediate resistance to available EGFR inhibitors—produced a high response rate in patients...

lung cancer

Pretreatment PET Metabolic Tumor Volume Is Associated With Outcome in Stage III NSCLC

In a study reported in the Journal of the National Cancer Institute, Ohri et al found that higher pretreatment metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) was associated with poorer overall survival and an increased risk of locoregional failure in...

lung cancer
issues in oncology

Decline in Proportion of Lung Cancer Patients Meeting Screening Criteria

In a study reported in a research letter in JAMA, Wang et al found that the proportion of patients with lung cancer who would have met U.S. Preventive Services Task Force (USPSTF) criteria for low-dose computed tomography (CT) lung screening decreased significantly between the periods of 1984 to...

lung cancer

European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement

In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...

lung cancer

Nivolumab Shows Activity in Advanced, Refractory Squamous NSCLC

In the phase II CheckMate 063 study reported in The Lancet Oncology, Rizvi et al found that the PD-1 inhibitor nivolumab (Opdivo) produced durable responses in some patients with advanced, refractory squamous non–small cell lung cancer (NSCLC) who had received at least two prior treatments....

lung cancer
issues in oncology

Outcomes of Phase II Basket Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies

In a basket trial (CUSTOM) reported in the Journal of Clinical Oncology, Lopez-Chavez et al performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer, or thymic malignancies and assigned those in any of five actionable...

lung cancer

Maintenance Sunitinib Improves Progression-Free Survival in Phase II Trial in Untreated Extensive-Stage Small Cell Lung Cancer

In the randomized phase II Cancer and Leukemia Group B (CALGB) 30504/Alliance trial reported in the Journal of Clinical Oncology, Ready et al found that sunitinib (Sutent) vs placebo maintenance following chemotherapy improved progression-free survival in patients with previously untreated...

lung cancer

No Improvement in Overall Survival With Addition of Anti-EGFR Antibody Necitumumab to First-Line Pemetrexed-Cisplatin in Metastatic Nonsquamous NSCLC

In the phase III INSPIRE trial reported in The Lancet Oncology, Paz-Ares et al found that the addition of the anti-EGFR IgG1 monoclonal antibody necitumumab to first-line pemetrexed (Alimta)-cisplatin did not improve overall survival in patients with previously untreated stage IV nonsquamous...

breast cancer
lung cancer

Aurora Kinase A Inhibitor Alisertib Active in Solid Tumors

In a phase II study reported in The Lancet Oncology, Melichar et al found that the oral aurora kinase A inhibitor alisertib was active in solid tumors, particularly breast cancer and small cell lung cancer. Aurora kinases play central roles in mitosis. Inhibition of aurora kinase A, which is...

lung cancer

FDA Analysis Explores Relationship Between Response Rate and Survival at Trial and Patient Levels in Advanced NSCLC Studies

In a U.S. Food and Drug Administration (FDA) analysis of randomized trials in advanced non–small cell lung cancer (NSCLC) reported in the Journal of Clinical Oncology, Blumenthal et al found a strong correlation between response rate and progression-free survival at the trial level and a...

lung cancer

Japanese Phase III Trial Shows No Survival Benefit of First-Line Weekly Cisplatin/Docetaxel vs Docetaxel in Elderly Patients With Advanced NSCLC

In a Japanese phase III trial (Intergroup Trial JCOG0803/WJOG4307L) reported in the Journal of Clinical Oncology, Abe et al found no overall survival benefit of weekly cisplatin/docetaxel vs standard docetaxel in the first-line treatment of elderly patients with advanced non–small cell lung...

lung cancer

Overall Survival Analysis of LUX-Lung 3 and LUX-Lung 6 Indicates Improvement With Afatinib in Subgroup of EGFR-Mutant Lung Cancer

In an analysis of overall survival in the phase III LUX-Lung 3 and LUX-Lung 6 trials reported in The Lancet Oncology, Yang et al found no significant difference between afatinib (Gilotrif) vs pemetrexed (Alimta)-cisplatin (LUX-Lung 3) or vs gemcitabine-cisplatin (LUX-Lung 6) in previously...

lung cancer
cns cancers

Crizotinib Produces Systemic and Intracranial Disease Control in Patients With Advanced ALK-Rearranged NSCLC and Brain Metastases

In a retrospective analysis reported in the Journal of Clinical Oncology, Costa et al found that crizotinib (Xalkori) treatment resulted in high systemic and intracranial disease control rates in patients with ALK-rearranged non–small cell lung cancer (NSCLC) who had asymptomatic brain...

lung cancer

No Benefit of High- vs Standard-Dose Radiotherapy or for Addition of Cetuximab to Chemoradiation in Stage IIIA or IIIB NSCLC

As reported in The Lancet Oncology by Bradley and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or for addition of cetuximab (Erbitux) to concurrent paclitaxel-carboplatin chemoradiation in patients with...

lung cancer

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...

lung cancer

Thoracic Radiotherapy Benefits Patients With Extensive-Stage Small Cell Lung Cancer Who Responded to Chemotherapy

In a phase III trial reported in The Lancet, Slotman et al found that while thoracic radiotherapy vs no thoracic radiotherapy was not associated with a significant improvement in 1-year overall survival, the primary endpoint of the study, it significantly improved 2-year overall survival and...

lung cancer

No Benefit of COX-2 Inhibitor Apricoxib in Combination With Docetaxel or Pemetrexed in Second-line Treatment of Patients With Biomarker-Selected NSCLC

In a phase II study reported in the Journal of Clinical Oncology, Edelman et al found no benefit of adding the daily COX-2 inhibitor apricoxib to second-line docetaxel or pemetrexed (Alimta) in patients with non–small cell lung cancer (NSCLC) who exhibited suppressed levels of the urinary...

lung cancer

Patients With Prior Cancer Excluded From Most Lung Cancer Trials

In a study reported in the Journal of the National Cancer Institute, Gerber et al found that patients with prior cancer were excluded from most clinical trials in lung cancer, including nearly all with overall survival as a primary endpoint. The study involved review of data from 51 lung cancer...

lung cancer

First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC

In a phase III PROFILE 1014 trial reported in The New England Journal of Medicine, Solomon et al found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in first-line treatment of advanced ALK-positive non–small cell lung cancer (NSCLC)....

lung cancer

No Survival Difference but Greater Morbidity With Etoposide/Cisplatin vs Carboplatin/Paclitaxel With Concurrent Radiotherapy for Stage III NSCLC

In an analysis of Veterans Health Administration data reported in the Journal of Clinical Oncology, Santana-Davila et al found that etoposide/cisplatin resulted in no overall survival difference but greater morbidity compared with carboplatin/paclitaxel used concurrently with radiotherapy in...

lung cancer

Dacomitinib Shows Activity in First-Line Treatment of Patients With Clinically or Molecularly Selected Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Jänne et al found that the pan-HER inhibitor dacomitinib was active in first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations or clinical characteristics associated with response to EGFR...

lung cancer

No Overall Survival Difference for Amrubicin vs Topotecan in Second-Line Treatment of Small Cell Lung Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Pawel et al found no difference in overall survival with amrubicin vs topotecan as second-line therapy in patients with first-line sensitive or refractory small cell lung cancer. An overall survival benefit of amrubicin was observed ...

lung cancer

Estimated Cost-Effectiveness of Low-Dose CT Screening for Lung Cancer

The National Lung Screening Trial (NLST) showed that low-dose computed tomography (CT) screening reduced lung cancer mortality compared with chest radiography. In a cost-effectiveness analysis in NLST reported in The New England Journal of Medicine, Black et al found that low-dose CT screening was...

lung cancer

Outcomes With Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy in Medicare Patients With Early-Stage NSCLC

In a study on use of the most common definitive therapies for non–small cell lung cancer (NSCLC) in Medicare patients reported in JAMA Surgery, Shirvani et al found that lobectomy was associated with improved outcome vs sublobar resection and that stereotactic ablative radiotherapy may be of...

lung cancer

Good Results With Stereotactic Body Radiation Therapy Plus Erlotinib in Limited but Progressive Metastatic NSCLC

In a phase II study reported in the Journal of Clinical Oncology, Iyengar et al found that stereotactic body radiation therapy plus erlotinib (Tarceva) resulted in infrequent recurrence in radiation therapy–treated sites and was associated with prolonged progression-free survival and overall...

lung cancer
issues in oncology

Crizotinib Highly Active in ROS1-Rearranged NSCLC

In a study reported in The New England Journal of Medicine, Shaw et al found that crizotinib (Xalkori) produced a high response rate in patients with ROS1-rearranged non–small cell lung cancer (NSCLC). Chromosomal rearrangements in ROS1, which encodes the proto-oncogene receptor tyrosine...

lung cancer
issues in oncology

Predictive Ability of CT Screen-Detected Nodule Volume, Diameter, and Volume-Doubling for Lung Cancer in NELSON Trial

The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis among screened Dutch participants reported in Lancet Oncology, Horeweg and colleagues identified screen-detected...

lung cancer
issues in oncology

Performance of Lung Cancer Low-Dose CT Screening With Increasing Screening Interval in NELSON Trial

The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis of screening test performance among Dutch participants reported in Lancet Oncology, Horeweg and colleagues found...

lung cancer

Overuse and Underuse of Recommended Imaging for Lung Cancer Staging in National VA Cohort

In a study reported in the Journal of Clinical Oncology, Backhus et al found that imaging guideline recommendations for staging of locally advanced lung cancer were often not followed in a national Veterans Affairs (VA) cohort. Study Details The study involved 3,808 patients with stage IIB, IIIA, ...

lung cancer

No Progression-Free Survival Benefit of Dacomitinib vs Erlotinib Overall or in KRAS Wild-Type Disease in Pretreated Advanced NSCLC

In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...

lung cancer

No Survival Benefit With Pan-HER Tyrosine Kinase Inhibitor Dacomitinib vs Placebo in Pretreated Advanced NSCLC

In the phase III NCIC CTG BR.26 Trial reported in The Lancet Oncology, Ellis et al found that treatment with the irreversible pan-HER tyrosine kinase inhibitor dacomitinib was not associated with an overall survival benefit compared with placebo in patients with pretreated advanced or...

lung cancer

ASCO Endorses Guideline for Molecular Testing to Select Lung Cancer Patients for EGFR and ALK Inhibitor Treatment

ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association of Molecular Pathologists (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor ...

lung cancer

New ALK Inhibitor Alectinib Shows Activity vs Crizotinib-Resistant NSCLC

In the phase I portion of a phase I/II study reported in The Lancet Oncology, Gadgeel et al found that the novel ALK inhibitor alectinib showed activity against systemic disease and brain metastases in patients with non–small cell lung cancer (NSCLC) resistant to the ALK inhibitor crizotinib...

lung cancer

European Phase III Trial Suggests Benefit of Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

In a European phase III trial reported in The Lancet, Slotman et al found benefits of thoracic radiotherapy in patients with extensive-stage small cell lung cancer who had responded to chemotherapy and had received prophylactic cranial radiotherapy. Although thoracic radiotherapy did not...

lung cancer

Meta-Analysis Shows No Overall Survival Benefit of Six vs Fewer Planned Cycles of First-Line Platinum-Based Chemotherapy in Advanced NSCLC

In a systematic review and meta-analysis of individual patient data reported in The Lancet Oncology, Rossi et al found no overall survival benefit with six vs fewer than six planned cycles of first-line platinum-based treatment in patients with advanced non–small cell lung cancer (NSCLC). A...

lung cancer

SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer

In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...

lung cancer

Small but Statistically Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC

In the phase III REVEL trial reported in The Lancet, Garon et al found that the addition of the  antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to docetaxel produced a statistically significant improvement in overall survival as second-line treatment in patients with non–small...

lung cancer
issues in oncology

ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma

The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...

lung cancer
issues in oncology

Comprehensive Molecular Profiling of Lung Adenocarcinoma

The Cancer Genome Atlas Research Network has recently reported its comprehensive molecular profiling of lung adenocarcinoma in Nature. Findings included a high rate of somatic mutations including alterations in tumor-suppressor genes, chromatin-modifying genes, and RNA-splicing genes and suggested...

Advertisement

Advertisement



Advertisement